Xenon Pharmaceuticals Inc.

NasdaqGM:XENE Stock Report

Market Cap: US$3.2b

Xenon Pharmaceuticals Valuation

Is XENE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XENE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: XENE ($43) is trading above our estimate of fair value ($38.11)

Significantly Below Fair Value: XENE is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for XENE?

Other financial metrics that can be useful for relative valuation.

XENE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-11x
PEG Ration/a

Price to Book Ratio vs Peers

How does XENE's PB Ratio compare to its peers?

The above table shows the PB ratio for XENE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average30.6x
INBX Inhibrx
38.3x25.5%US$1.7b
BPMC Blueprint Medicines
44.4x66.2%US$5.8b
SWTX SpringWorks Therapeutics
5.9x17.8%US$3.7b
SMMT Summit Therapeutics
33.9xn/aUS$2.6b
XENE Xenon Pharmaceuticals
3.5x23.7%US$3.2b

Price-To-Book vs Peers: XENE is good value based on its Price-To-Book Ratio (3.5x) compared to the peer average (30.6x).


Price to Earnings Ratio vs Industry

How does XENE's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.6%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.6%
n/an/an/a
No more companies

Price-To-Book vs Industry: XENE is expensive based on its Price-To-Book Ratio (3.5x) compared to the US Biotechs industry average (2.3x).


Price to Book Ratio vs Fair Ratio

What is XENE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XENE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate XENE's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XENE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$43.00
US$57.44
+33.6%
9.3%US$65.00US$45.00n/a17
Mar ’25US$46.84
US$57.38
+22.5%
9.3%US$65.00US$45.00n/a17
Feb ’25US$46.43
US$54.41
+17.2%
11.3%US$63.00US$45.00n/a16
Jan ’25US$46.06
US$53.63
+16.4%
11.2%US$63.00US$45.00n/a15
Dec ’24US$36.80
US$51.96
+41.2%
9.2%US$60.00US$45.00n/a14
Nov ’24US$31.22
US$51.86
+66.1%
8.3%US$60.00US$46.00n/a14
Oct ’24US$34.16
US$52.27
+53.0%
8.5%US$60.00US$46.00n/a15
Sep ’24US$39.73
US$52.27
+31.6%
8.5%US$60.00US$46.00n/a15
Aug ’24US$37.38
US$52.20
+39.6%
8.1%US$60.00US$46.00n/a15
Jul ’24US$38.50
US$52.20
+35.6%
8.1%US$60.00US$46.00n/a15
Jun ’24US$38.65
US$52.20
+35.1%
8.1%US$60.00US$46.00n/a15
May ’24US$39.98
US$51.33
+28.4%
9.7%US$60.00US$44.00n/a15
Apr ’24US$35.79
US$50.60
+41.4%
9.2%US$60.00US$44.00n/a15
Mar ’24US$40.35
US$50.40
+24.9%
9.1%US$60.00US$44.00US$46.8415
Feb ’24US$39.18
US$50.40
+28.6%
9.1%US$60.00US$44.00US$46.4315
Jan ’24US$39.43
US$50.13
+27.1%
9.0%US$60.00US$44.00US$46.0615
Dec ’23US$36.93
US$49.43
+33.8%
7.7%US$60.00US$44.00US$36.8014
Nov ’23US$37.12
US$50.31
+35.5%
7.9%US$60.00US$43.00US$31.2213
Oct ’23US$36.10
US$49.92
+38.3%
8.6%US$60.00US$43.00US$34.1612
Sep ’23US$39.53
US$49.92
+26.3%
8.6%US$60.00US$43.00US$39.7312
Aug ’23US$31.68
US$45.82
+44.6%
15.3%US$60.00US$35.00US$37.3811
Jul ’23US$30.79
US$44.70
+45.2%
14.4%US$60.00US$36.00US$38.5010
Jun ’23US$26.68
US$44.10
+65.3%
10.0%US$50.00US$36.00US$38.6510
May ’23US$28.27
US$44.90
+58.8%
7.7%US$50.00US$40.00US$39.9810
Apr ’23US$32.36
US$44.90
+38.8%
7.7%US$50.00US$40.00US$35.7910
Mar ’23US$31.76
US$45.70
+43.9%
7.5%US$50.00US$40.00US$40.3510

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.